<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899843</url>
  </required_header>
  <id_info>
    <org_study_id>BSMMU/2021/3959</org_study_id>
    <nct_id>NCT04899843</nct_id>
  </id_info>
  <brief_title>Effectiveness of Zinc Supplementation With Topical Retinoids in Acne Vulgaris Patients</brief_title>
  <official_title>Effectiveness of Zinc Supplementation With Topical Retinoids in Acne Vulgaris Patients: Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is 8 weeks, randomized, double-blind, placebo-controlled trial to assess&#xD;
      the effect of zinc sulphate on symptoms of mild and moderate acne vulgaris in 122 patients.&#xD;
      Participants will be assessed at baseline, and 8 weeks. Subjects will be randomized to&#xD;
      receive either 20 mg elemental zinc daily or 20 mg placebo tablet daily for 8 weeks. The&#xD;
      primary outcome is the measure of the GAGS score and the secondary measure includes serum&#xD;
      zinc level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acne vulgaris (AV) is the eighth most prevalent disease worldwide with a prevalence of 7% in&#xD;
      Bangladesh. Acne is a self-limiting condition, it may cause significant psychological and&#xD;
      social problems, depression, disfigurement and scarring that can persist for a lifetime.&#xD;
      Multiple factors contribute to acne pathogenesis including increased sebum production,&#xD;
      aberrant keratinization of the pilosebaceous duct, bacteria such as Cutibacterium acnes,&#xD;
      hormonal influences, the skin microbiome, and chronic inflammation. Relapse rates in patients&#xD;
      with acne after treatment with standard of care vary between 10% and 60%. Recent trials&#xD;
      attempted to assess the effect of zinc in reducing the severity of symptoms of acne vulgaris&#xD;
      patients. This study evaluates whether there is any role of zinc in reducing acne symptoms&#xD;
      between those who did and did not receive zinc in an 8 weeks period. This includes 122 acne&#xD;
      vulgaris patients who were recruited from Dermatology and Venereology OPD of BSMMU.&#xD;
      Participants will take either 20 mg elemental zinc daily in the form of zinc sulphate tablet&#xD;
      or 20 mg placebo tablet daily for 8 weeks. Initially, baseline serum zinc level will be&#xD;
      measured and repeated again after 8 weeks of intervention. A baseline acne symptoms survey&#xD;
      will be done by GAGS score and also repeated at 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Newly diagnosed Acne vulgaris patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acne vulgaris severity score assessment</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Assess the severity score of acne vulgaris symptoms by GAGS(Global Acne Grading System) at baseline, and after 8 weeks.&#xD;
And compare the score between two groups. GAGS scores : 1-18 Mild, 19-30 Moderate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical assessment</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Serum zinc level is assessed at baseline and after 8 weeks intervention. Compare the serum zinc level between two group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm includes 61 acne vulgaris patients receiving topical retinoids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm includes 61 acne vulgaris patients receiving topical retinoids</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc sulphate tablet 20 mg</intervention_name>
    <description>Zinc sulphate tablet 20 mg daily orally for 8 weeks along with topical retinoids.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo tablet 20 mg</intervention_name>
    <description>Placebo tablet 20 mg daily orally for 8 weeks along with topical retinoids</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed mild and moderate AV patients diagnosed by a dermatologist of the&#xD;
             Department of Dermatology and Venereology,&#xD;
&#xD;
          -  Serum zinc &lt;70 microgram/dl,&#xD;
&#xD;
          -  Age: 11-35 years,&#xD;
&#xD;
          -  Sex: Both male and female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving topical retinoids within the last two months,&#xD;
&#xD;
          -  Pregnancy and lactation,&#xD;
&#xD;
          -  History of corticosteroids, oral contraceptive pills, zinc, and iron intake,&#xD;
&#xD;
          -  Suffering from active malignancy or any cosmetic induced acne&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Md. Sayedur Rahman, MBBS, Mphil</last_name>
    <role>Study Chair</role>
    <affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Humayra Rumu, MBBS</last_name>
    <phone>01797873653</phone>
    <email>humayra.rumu@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prof. Md. Sayedur Rahman, MBBS, Mphil</last_name>
    <phone>01971840757</phone>
    <email>srkhasru@bsmmu.edu.bd</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Basic Science and Paraclinical Science of BSMMU</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Humayra Rumu, MBBS</last_name>
      <phone>01797873653</phone>
      <email>humayra.rumu@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Prof. Md. Sayedur Rahman, MBBS, Mphil</last_name>
      <phone>01971840757</phone>
      <email>srkhasru@bsmmu.edu.bd</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Dr. Humayra Rumu</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>AV Zinc GAGS Serum zinc level</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

